Startseite Aktuelles Seminare Yvette Meißner : Inflammation, rheumatoid arthritis and cardiovascular disease
Nov 18

Yvette Meißner : Inflammation, rheumatoid arthritis and cardiovascular disease

Lecture and references available


Thursday, 29 November 2018 || Time: 14:00


Chronic inflammation lecture: Inflammation, rheumatoid arthritis and cardiovascular disease
Yvette Meißner

Some of the pivotal pro-inflammatory mediators, including the cytokines tumor necrosis factor alpha (TNFα), interleukin 1 (IL-1) and interleukin 6 (IL-6), as well as the acute-phase reactant C-reactive protein (CRP), are involved in atherogenesis and eventually in the development of coronary artery diseases. The autoimmune disease of rheumatoid arthritis is characterized by chronic inflammation primarily affecting the joints. However, patients with rheumatoid arthritis have an increased burden of cardiovascular morbidity and mortality compared to the general population. This lecture will summarize current insights into chronic inflammation as a link between cardiovascular events and rheumatoid arthritis. Furthermore, experiences from the German observational cohort RABBIT (Rheumatoid Arthritis: Observation of Biologic Therapy) with regard to cardiovascular diseases will be presented.


  1. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690-7.
  2. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524-9.
  3. Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O’Fallon WM, Matteson EL. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 2003;48(1):54-8.
  4. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44(12):2737-45.
  5. Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol. 2011;7(7):399-408.
  6. van Vollenhoven RF. Unresolved issues in biologic therapy for rheumatoid arthritis. Nat Rev Rheumatol. 2011;7(4):205-15.
  7. Meissner Y, Zink A, Kekow J, Rockwitz K, Liebhaber A, Zinke S, Gerhold K, Richter A, Listing J, Strangfeld A. Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. Arthritis Res Ther. 2016;18(1):183.
  8. Behrouz R. The risk of ischemic stroke in major rheumatic disorders. J Neuroimmunol. 2014;277(1-2):1-5.
  9. Ovbiagele B, Nguyen-Huynh MN. Stroke epidemiology: advancing our understanding of disease mechanism and therapy. Neurotherapeutics. 2011;8(3):319-29.
  10. Navi BB, Reiner AS, Kamel H, Iadecola C, Elkind MSV, Panageas KS, DeAngelis LM. Association between incident cancer and subsequent stroke. Annals of Neurology. 2015;77(2):291-300.
  11. Meissner Y, Richter A, Manger B, Tony HP, Wilden E, Listing J, Zink A, Strangfeld A. Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort. Ann Rheum Dis. 2017;76(9):1583-90.
  12. Nicola PJ, Crowson CS, Maradit-Kremers H, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum. 2006;54(1):60-7.
  13. Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, Gabriel SE. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52(2):412-20.
  14. Meissner Y, Schäfer M, Manger B, Zänker M, Ochs W, Listing J, Strangfeld A. THU0142 The prognosis of heart failure in patients with rheumatoid arthritis. 2018;77(Suppl 2):291-2.
  15. Liao KP. Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc Med. 2017;27(2):136-40.
  16. Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015;11(12):693-704.
  17. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63(4):522-9.
  18. Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernan MA, Ridker PM, Mozaffarian D. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362-70.
  19. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, Group CT. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-31.
  20. Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ, Investigators C. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2018.


when: 14:00-15:00, weekly, every Thursday
where: DRFZ, Seminar room 3, Charitéplatz 1
visitors: Virchowweg 12

Hier klicken um die Karte von Google Maps zu laden

Anmeldung & Kontakt

• Are you familiar with chronic inflammatory diseases?
• Have you heard that any organ can be affected?
• Joints, skin, kidneys, nerves, intestines – all?
• understand one inflammatory disease – cure them all?

…. these and further topics will be covered in the new Lecture Series given by our Postdoc Fellows.

miRNA +++ drug discovery +++ imaging +++ cancer +++ RNA-based gene regulation +++ immune checkpoints as therapeutic targets +++ T cells +++ mass cytometry ++ plasma cell targeting +++ RA and cardiovascular disease +++ optical ethods +++ stromal niches

Stefan Frischbutter +++ Patrick Maschmeyer +++ Randall Lindquist +++ Gitta Heinz +++ Marina Babic-Cac +++ Shintaro Hoyjo +++ Axel Schulz +++ Laleh Khodadadi +++ Yvette Meissner +++ Asylkhan Rakhymzhan +++ Daniel Schulz

In the ScienceCampus we aim at transferring research and therapeutic concepts from one disease to another – across disciplines – for a fast translation into the clinic.

Geschäftsstelle Leibniz WissenschaftsCampus Chronische Entzündung
Mag. Dr. Elke Luger
Tel +49-(0)30-28460-737

Weitere Seminare

Apr 2019
Seminar | Lecture Series on Chronic Inflammation

Gitta Heinz: Next Generation Sequencing to investigate Immunity and Chronic Inflammation

Apr 2019
Seminar | Lab-Seminar

Asylkhan Rakhymzhan: Three-photon imaging of various mouse organ structures

Mai 2019
Seminar | Lecture Series on Chronic Inflammation

Marta Ferreira Gomes: The Importance of Fungal Infections – The Candida albicans Case

Mai 2019
Seminar | Lab-Seminar

Adrian Madrigal-Avilés: Different regulation in glucose metabolism between Th1 and Th2 cells

Mai 2019
Seminar | Epidemiologisches Doktorandenseminar

Jens Klotsche: Einfluss des Zeitpunktes des Therapiestartes mit Biologika auf die Langzeitprognose der JIA

Mai 2019
Seminar | Lecture Series on Chronic Inflammation

Randy Lindquist: Chronic Inflammation at Ectopic Sites

Mai 2019
Seminar | Lab-Seminar

Weijie Du: The epigenetic imprinting of human memory lymphocytes

Mai 2019
Seminar | Lecture Series on Chronic Inflammation

Frederik Heinrich: Analysis and Visualization of RNAseq Data

Mai 2019
Seminar | Lab-Seminar

Anna Pascual-Reguant: Analysis of rare cell populations in situ using MELC

Mai 2019
Seminar | Lecture Series on Chronic Inflammation

Annette Lahmann: Development and Maintenance of T Follicular Helper Cells

Mai 2019
Seminar | Lab-Seminar

Manuela Frese-Schaper: Topoisomerase I inhibitors as a potential new treatment for systemic lupus erythematosus

Mai 2019
Seminar | Epidemiologisches Doktorandenseminar

Kirsten Minden, Nadine Betenstehl: Komorbiditäten bei Erwachsenen mit juveniler idiopathischer Arthritis